000 03587naa a22005537i 4500
001 UMUN-OA-20261005-AI-049
003 local
005 20261005174826.0
006 m o d
007 cr||||||||||||
008 261005s2019 xx o u000 0 eng d
024 7 _a10.1021/acs.chemrev.8b00728
_2doi
035 _a(local)OpenAlex:W2959938226
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aXin Yang
_eauthor.
245 1 0 _aConcepts of Artificial Intelligence for Computer-Assisted Drug Discovery /
_cXin Yang; Yifei Wang; Ryan Byrne [and others].
264 1 _a[Place of publication not identified] :
_bAmerican Chemical Society,
_c2019.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aArtificial intelligence (AI), and, in particular, deep learning as a subcategory of AI, provides opportunities for the discovery and development of innovative drugs. Various machine learning approaches have recently (re)emerged, some of which may be considered instances of domain-specific AI which have been successfully employed for drug discovery and design. This review provides a comprehensive portrayal of these machine learning techniques and of their applications in medicinal chemistry. After introducing the basic principles, alongside some application notes, of the various machine learning algorithms, the current state-of-the art of AI-assisted pharmaceutical discovery is discussed, including applications in structure- and ligand-based virtual screening, de novo drug design, physicochemical and pharmacokinetic property prediction, drug repurposing, and related aspects. Finally, several challenges and limitations of the current methods are summarized, with a view to potential future directions for AI-assisted drug discovery and design.
540 _aCreative Commons Attribution-NonCommercial-NoDerivatives (licence family recorded by the source; version not supplied in metadata).
_uhttps://openalex.org/W2959938226
546 _aIn English.
588 0 _aDescription generated from OpenAlex bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Artificial Intelligence.
650 4 _aartificial intelligence in drug discovery
650 4 _adeep learning
650 4 _avirtual screening
650 4 _aligand-based virtual screening
650 4 _astructure-based virtual screening
650 4 _ade novo drug design
653 _aB. Sc. Artificial Intelligence
653 _aUMUN open access collection
653 _aartificial intelligence
655 4 _aReview articles.
700 0 _aYifei Wang
_eauthor.
700 0 _aRyan Byrne
_eauthor.
700 0 _aGisbert Schneider
_eauthor.
700 0 _aShengyong Yang
_eauthor.
773 0 _tChemical Reviews
_gVol. 119, no. 18, (2019), pages/article 10520-10594
_x0009-2665
856 4 0 _uhttps://doi.org/10.1021/acs.chemrev.8b00728
_yRead open-access publication
_zOpen access. Access and licence reported by the source; this host could not be independently checked by automation.
_70
884 _aCourse selection and automated MARC21 enrichment from OpenAlex metadata.
_g20261005
_khttps://openalex.org/W2959938226
_qlocal
942 _n0
999 _c606
_d606